| Textual Information(1) |
1. The Consolidated audited financial results are prepared in accordance with the Accounting Standards Prescribed urder Section 133 of the Companies Act,2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. 2. The company has signed a Memorandum of understanding (MOU) (dated 15th July 2024) and share sale agreement (dated 08 October 2024) with the Depot Pharmacy Yego Ltd. (Rwanda, East Africa based company) having corporate office at Plot No B1 Kigali City Market, Nyarugenge Kigali-20093, Rwanda East Africa. The company has invested 51% stake in Depot Pharmacy Yego Ltd. The transaction to acquire the DPYL was 08-10-2024 but Actual transaction is completed on 16-01-2025 which is the acquisition date for the company. The company has incorporated a subsidiary on 27th December 2024 in the name of Grande Etoile Pharmaceuticals Limited with 50.92% of share holidng in the same company. 3. The Statutory Auditors of the Company have audited of the above results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 4. There were no investor complaints known to the Company outstanding at the beginning and at the end of the half year ended on March 31, 2026. 5. The results of the Company are also available for investors at www.medicamenorganics.com and www.nseindia.com. 6. The above Consolidated audited financial results for the Half year ended and year ended March 31, 2026 have been prepared by the Company were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their respective meeting held on May 29, 2026, Above results has been audited by the statutory auditors of the company. 7. The company has received intimation from suppliers regarding their status under Micro, Small and Medium Enterprises Development Act 2006 and disclosures relating to the amount unpaid as at year end, as required under the said Act, have been provided. The Company has provided the interest on outstanding from supplier under Micro, Small and Medium Enterprises as on 31-03-2026. 8. The Results for the half-year ended and year ended March 31st, 2026 are audited by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 9. These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards (AS) prescribed section 133 of the Companies Act 2013 (the Act) read with relevant rules issued thereunder and the other accounting principles generally accepted in India. 10. The Earning Per Share (EPS) has been computed in accordance with the Accounting Standard on Earnings Per Share (AS 20). EPS for the half year ended March 31st, 2026, September 30th, 2025, and March 31st 2025 are not annuualised. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earnings per share in accordance with the Accounting Standard 20. 11. The comparative results for the half-year ended and year ended March 31, 2026 have been audited by the statutory auditors of the Company. 12. The figures for the half-year ended March 31st, 2026 are balancing figures between audited figures in respect of the full financial year ended March 31st, 2026 and the unaudited half-year ended September 30th 2025. 13. The company has issued 31,00,000 equity shares of Rs 10 each at a premium of Rs 24 each by way of initial public offer (IPO) and got listed on Emerge Platform of National Stock Exchange of India Limited on June 28th, 2024. 14. CONTINGENT LIABILITIES AND PENDING LITIGATIONS 14A Contingent Liabilities Particulars Next date of Hearing As at 31-03-2026 a. Case against the company filed by Prakash Parcel Services Ltd. 20-08-2026 2.34 b. Case against the company filed by Multani Pharmaceuticals 29-05-2026 7.18 c. Margin money (FDR) for Bank Guarantee on behalf of third party (Margin FDR of Rs 56200) 5.62 14B Name of the statute Nature of the dues Amount (Rs. in lakhs) Financial Year Description Forum where dispute is pending Income Tax Department Income tax 13.27 AY 2017-18 Assessment year Commissioner of income tax (Appeal) GST Difference in output tax liability & ITC claimed 17.74 2022-23 Reply is to be filed Deputy Commissioner (Assessment)-2 Haridwar 14C Detail of Pending Litigation Name of the Party Nature of the dues Amount (Rs. in lakhs) Next date of Hearing Description Forum where dispute is pending Europa Biocare P Ltd Civil Case 7.23 29-07-2026 The company has filed recovery suit (civil case) against the defaulter party Rohini (Court) M/S Wafture Healthcare P Ltd Civil Case 5.7 19-09-2026 The company has filed recovery suit (civil case) against the defaulter party Rohini (Court) Paseca Health Care Civil Case 5.53 29-07-2026 The company has filed recovery suit (civil case) against the defaulter party Rohini (Court) Ujjwal Overseas Civil Case 17.17 29-07-2026 The company has filed recovery suit (civil case) against the defaulter party Rohini (Court) Mex Life Care Ltd Civil Case 13.72 01-08-2026 The company has filed recovery suit (NI Act case) against the defaulter party Rohini (Court) 15. During the period ended March 31, 2025, the Company came up with the public issue of 31,00,000 equity shares of Face value of Rs 10/- each (equity shares) with the price band of Rs 32 to 34 through Book Building Method, IPO was open for subscription from Friday, June 21, 2024 to Tuesday, June 25, 2024. The Company has allotted 31,00,000 equity shares of Face value of 10/- each (equity shares) for cash at a price of Rs 34/- per equity share (including a share premium of Rs 24/- per equity share) aggregating to Rs 1054.00 Lakhs on Wednesday, June 26, 2024. The equity shares of the Company got listed with Emerge platform of National Stock Exchange of India Limited on June 28, 2024. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Rs. In Lakhs Object of the Issue as per Prospectus Utilisation Planned as per prospectus Amount actually Utilised by the company Balance available Revised Object # Utilisation Planned as per prospectus and revised object Amount Pending for Utilisation Funding of expenses proposed to be incurred towards Product registration in the international markets 300 137.56 162.44 -162.44 - - Plant updation and increase in production capacity 225 225 - - - - Funding working capital requirements of our Company 400 400 0 162.44 162.44 - General corporate purposes 39 39 - - - - Issue Related Expenses 90 90 - - - - TOTAL 1054 891.56 162.44 162.44 162.44 - # Funding of expenses proposed to be incurred towards Product registration in the international markets of Rs.300 Lakhs, out of the amount, Rs 162.44 (In lakhs) (representing 15.41% of the IPO proceeds) remains unutilized as 30th September 2025 (the “Unutilized Amount”). however, the Company no longer requires these funds for such purpose. on February 26th, 2026, Special resolution passed to consider and approve variation in the objects of the issue relating to initial public offering (ipo) for which amount was raised through prospectus. The unutilized IPO proceeds of Rs. 162.44 (In lakhs) i.e. 15.41% of IPO proceeds, is intended to be utilized towards the following purposes. S No Object of the Issue as per DRHP Utilisation Planned as per prospectus Amount actually Utilised by the company Balance available for Utilisation Revised Object as per Special resolution Amount to be funded from the IPO Proceeds 1 expenses proposed to be incurred towards Product registration in the international markets 300 137.56 162.44 To meet out the working capital requirements of our company 162.44 16 The Company has written off an amount of Rs. 33.09 Lakhs being outstanding balance of GST refund, which is no longer recoverable from the GST department. 17 The Goods and Services Tax (GST) department, Uttarakhand, is currently conducting a scrutiny of the Company's tax returns for the Financial Year 2024–25. During the period, the Company has made a voluntary payment of Rs. 50.00 Lakh via Form GST DRC-03. The scrutiny proceedings are currently ongoing, and management believes that no additional material liability is expected to arise upon final assessment. Consequently, no further provision has been made in the financial statements. 18 During the financial year ended March 31, 2026, the Company came up with the preferential issue of 4,65,910 warrants convertible into equivalent number of fully paid-up equity shares of face value of Rs 10/- (Rupee Ten Only) each (Equity Shares) at the option of Allottees, in one or more tranches, within 18 (eighteen) months from the date of allotment at issue price of Rs 64.39/-. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. In Lakhs Object as disclosed in the offer document Nature Amount disclose in the Offer Document/ Postal Ballot Notice dated January 08, 2025 (Rs. In Lakhs) Actual Utilised Amount (as on March 31, 2026) Unutilised Amount (As on March 31, 2026) Remarks, If any (a) working capital requirements; 4,65,910 Share Warrants convertible into Equity Shares 299.99 298.24 - As on March 31, 2026, funds received against the warrants subscription money on 4,65,910 warrants amounted to Rs2,99,99,945,. The Company has spent total funds towards the objects disclosed in the offer document/Postal Ballot Notice. (b) general corporate purpose. 1.75 - Total Total 299.99 299.99 - 19 The Company resolved thru special resolution dated 24th January 2026 that the share warrants are now converted into Equity Shares 4,65,910 to Mr. Bal Kishan Gupta of fully paid-up equity shares of face value of Rs. 10/- (Rupee Ten Only) each (Equity Shares) and the issue price of Rs. 64.39/-. 20 Sundry creditors of the company include Rs. 40.21 Lakhs received in March 2025, from a foreign customer, M/s Escorts Pharmaceuticals Rwanda Limited (EPRL). No supplies were executed against this advance during the financial year ended March 31, 2026. Due to the ongoing geopolitical tensions and conflict situation in the East African region, including disruptions arising from the Rwanda–DRC border instability and war-like conditions, the Company has been facing significant logistical and transportation challenges in executing export shipments to Rwanda. Although advance/payment was received from Escort Pharmaceuticals, Rwanda, the export of goods could not be completed within the expected timeline due to uncertainty in cross-border movement, shipping constraints, safety concerns, and disruption in international trade routes. The matter is under continuous review, and the Company is coordinating with the customer and logistics partners for further course of action.” 21 For the purpose of consolidation of financial statements, Medicamen Organics Limited has considered the audited financial statements of Grande Etoile Pharmaceuticals Limited and Loire Cosmetics Limited in accordance with the applicable accounting standards and regulatory requirements. The books of accounts of the foreign subsidiary (Depot Pharmacy Yego Ltd) has not been consolidated in the consolidated financial results of Medicamen Organics Limited due to non availability of books of accounts. 22 Accounting Standard 21Consolidated Financial Statements is applied in the preparation and presentation of consolidated financial statements for a group of enterprises under the control of a parent. 23 Medicamen Organics Limited has a subsidiary namely Grande Etoile Pharmaceuticals Limited. Further, Grande Etoile Pharmaceuticals Limited has incorporated a subsidiary company namely Loire Cosmetics Limited on 03 September 2025 with a shareholding of 50.75%. Accordingly, Loire Cosmetics Limited has become a step-down subsidiary of Medicamen Organics Limited w.e.f. 03 September 2025. 24 Note on Write-off of Receivable from Medi Hub Organic Limited (Nepal) During the financial year, Grande Etoile Pharmaceuticals Limited (Subsidiary of Medicamen Organics Limited) had raised invoice of Rs. 110 Lakh on Medi Hub Organic Limited, Nepal towards provision of Consultancy Services relating to Design, Construction, Documentation, Product Development and Technology Transfer. Subsequent to continuous follow-up with the customer and a detailed assessment of the recoverability of the outstanding amount, management has observed that the project could not be implemented as originally envisaged due to changes in the client's business plans, financial constraints and discontinuation/deferment of the proposed activities for which the services were engaged. Further, despite repeated communications and recovery efforts, the customer has neither confirmed any payment schedule nor demonstrated the financial ability and intention to settle the outstanding dues. Considering the prolonged ageing of the receivable, uncertainty of recovery, cross-border enforcement challenges and applying the principle of prudence, management has concluded that the amount is no longer recoverable. Accordingly, the outstanding receivable of Rs.110 Lakhs (Rupees One Crore Ten Lakhs Only) from Medi Hub Organic Limited (Nepal) has been written off in the books of accounts and charged to the Statement of Profit & Loss as Bad Debts / Irrecoverable Trade Receivables during the year. 25 Balances of some debtors and creditors are subject to their confirmations. 26 As per the assessment of the management, the recoverable amount of assets is higher than it carrying value and hence no impairment of assets needs to be recorded in the financial statements. 27 Previous year/period's figures have been regrouped/reclassified wherever necessary to correspond with the current period's classification for comparison. 28 As the Company's business activity falls within a single primary business segment i.e. the disclosure requirements as per AS 17 Segment Reporting are not applicable. |